Table 1 Clinical characteristics of patients.

From: Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer

 

Sunitinib (N = 52)

Sorafenib (N = 55)

Median age (years)

51(18–81,44–62)

58(29–79,47–64)

Sex (male)

40(78%)

41(75%)

Median follow-up (months)

49(32–78, 33–59)

46(29–102, 34–50)

Median PFS

14.25(1.5– >78, 6.6– >35)

13.4(3.7– >102, 6.7– >36)

Median OS

30(1.5– >78, 17.1– >41.6)

31.5(3.7– >102, 19.4– >41)

Common metastasis sites

 Lung

45(86%)

43(78%)

 Lymph nodes

25(48%)

23(42%)

 Bone

11(21%)

13(24%)

 Liver

9(17%)

6(11%)

Risk factors*

 0 (favourable)

10(19%)

12(22%)

 1–2 (intermediate)

38(73%)

39(71%)

 ≥3 (poor)

4(8%)

4(7%)

Fuhrman grade

 1

1(2%)

4(7%)

 2

28(54%)

27(49%)

 3

19(36%)

19(35%)

 4

4(8%)

5(9%)

T stage

 1–2

28(54%)

31(56%)

 ≥3

24(46%)

24(44%)

  1. Data are median (range, IQR) or n (%). *Risk groups according to Memorial Sloan-Kettering Cancer Center prognostic factors, T stage is pathological stage.
Back to article page